Table 1 Potential driver genes in each tumor.

From: Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor

Group

p53 status

Sample

Driver genes

TSG/oncogene

VAF

Dayse

Brca1co/co; MMTV-Cre

Wild type

476PT

Adam20

PRE-TSG

0.33

402

Prdm2

TSG

0.26

Ttn

PRE-TSG

0.23

Ttc28

PRE-TSG

0.21

Kansl2

PRE-TSG

0.21

153PT

Arhgef11

PRE-TSG

0.37

440

Pbrm1

TSG

0.33

Ipo7

PRE-TSG

0.24

Psip1

Oncogene

0.21

153LMT

Plekha5

PRE-TSG

0.52

Arhgef11

PRE-TSG

0.28

1867-5L

Esrp1

TSG

0.12

673

1949-3L

Aff3

Oncogene

0.37

651

Kdr

Oncogene

0.13

Cyb5a

TSG

0.07

Frameshift

1949-5R

Trp53

TSG

0.87

651

Rasal1

TSG

0.46

Hspd1

TSG

0.06

958-5L

Trp53

TSG

0.82

929

Mms22l

Oncogene

0.14

Brca1co/co; p53+/co; Wap-Cre

'+/â–³a

2307-2R

Rere

Oncogene

0.33

342

Tpr

Oncogene

0.12

Cars

TSG

0.09

Rsf1

Oncogene

0.06

2307-5Rc

Ptch1

TSG

0.16

342

Birc3

Oncogene

0.01

2313-2L

Kras

Oncogene

0.41

342

Ralgds

Oncogene

0.31

Ptprb

TSG

0.12

Ranbp9

TSG

0.05

2384-5R

Rps6kb1

d

0.52

307

2388-3Rc

Stx3

PRE-TSG

0.04

330

'LOH/â–³b

2303-5R

Abcg2

TSG

0.40

371

Atm

TSG

0.03

2305-4L

Nras

Oncogene

0.80

342

2306-2Rc

Top1

PRE-TSG

0.12

342

2313-3Rc

Birc6

Oncogene

0.29

342

Smarce1

TSG

0.18

Traf6

Oncogene

0.17

Sf3b1

Oncogene

0.04

2313-4R

Rassf4

TSG

0.15

342

Akt3

Oncogene

0.03

2318-3R

Map4k1

TSG

0.37

365

Slit2

TSG

0.33

Yy1

Oncogene

0.31

Slx4

TSG

0.21

Prkcb

TSG

0.05

Vegfa

TSG/oncogene

0.04

2321-3L

Lad1

d

0.39

342

Adh5

PRE-TSG

0.07

2378-1L

Csmd1

TSG

0.41

330

Apc

TSG

0.39

Egfr

Oncogene

0.14

2384-2Rc

Dlx5

Oncogene

0.07

307

2404-3R

Nf1

TSG

0.86

326

Shprh

TSG

0.18

  1. aDeletion of one copy of exon 5 and 6 of p53 mediated by Wap-Cre-LoxP.
  2. bDeletion of two copies of exon 5 and 6 of p53. One copy deletion is mediated by Wap-Cre-LoxP, another one is naturally lost.
  3. cThe driver mutations in this tumor cannot be validated by Sanger sequencing.
  4. dThe gene is neither a TSG/oncogene nor a PRE-TSG/Oncogene but with high VAF.
  5. eDays to observe tumors.